Optellum ads

Across the United States, hospitals use Optellum’s AI platform to identify and manage lung nodules more efficiently, with clear financial return. With Virtual Nodule Clinic (VNC), Optellum provides end-to-end enterprise AI for lung nodule management. VNC is the only FDA-cleared AI for both pulmonologists and radiologists, automatically discovering patients from radiology reports, applying a reimbursable cancer risk score (Lung Cancer Prediction AI) from CT images, and supporting structured follow-up and care coordination within existing clinical teams. Each use of Optellum’s Lung Cancer Prediction AI is eligible for CMS reimbursement at $650, enabling health systems to fund earlier diagnosis, improve follow-up rates, and increase appropriate downstream procedures without adding staff. Find and prioritize more lung nodules - book your demo today!

Early detection saves lives, yet too many lung cancers remain hidden until they're too advanced to treat. Millions of patients with lung nodules need appropriate follow-up, yet current approaches often miss important details, and valuable information gets lost in complex datasets that are difficult to analyze manually. Optellum’s Lung Cancer Prediction AI technology, powered by the world's largest lung CT dataset, sees beyond what's visible. It surfaces risk earlier, enabling clinicians to identify and prioritize at-risk lung nodule patients for appropriate follow-up and treatment, supporting earlier intervention and better outcomes. FDA-cleared and with reimbursement of over $650 available per risk stratification, it also delivers sustainable value. Seamlessly integrated and clinically validated, Optellum helps transform how care teams identify lung cancer at an earlier stage. Ready to catch more cancers earlier? Book a demo at https://lnkd.in/gi692DbV

Bring the future of early lung cancer diagnosis to your team with Optellum’s Virtual Nodule Clinic (VNC). Powered by advanced AI, our all-in-one clinical decision support tool—the only FDA-cleared AI for both pulmonologists and radiologists—identifies, tracks, manages, and risk-stratifies lung nodules, helping clinicians prioritize at-risk patients and make treatment decisions with confidence. Seamlessly integrated, clinically validated, and designed to accelerate early diagnosis, Optellum VNC empowers every thoracic care team to deliver precision care, faster. Ready to enhance patient outcomes? Book a demo at https://lnkd.in/em7aNgQk

First-of-its-kind health economic study on AI in thoracic imaging. As the number of CT scans continues to rise, so do health systems detect more incidental lung nodules. This creates both clinical and economic challenges in identifying which nodules are high-risk and require immediate follow-up. In the first lifetime payer-perspective economic analysis of an AI-assisted risk stratification tool for lung nodules, Drs. Caroline Godfrey, Fabien Maldonado, Eric Grogan and colleagues at the Vanderbilt University Medical Center report that clinicians using Optellum's FDA-cleared Lung Cancer Prediction (LCP) AI-assisted risk stratification can improve life expectancy and only add about $114 in additional healthcare costs per patient over a lifetime. Learn how Optellum's clinically validated AI helps health systems improve lung cancer diagnosis while maintaining practical and sustainable delivery of healthcare. 👉 Read the full story here: https://lnkd.in/gQVj3t7U #LungCancer #HealthcareAI #ValueBasedCare #PrecisionMedicine #HealthEconomics #DigitalHealth #MedTech #HealthTech #LungNoduleManagement #MalignancyRiskPrediction #CPTCodes #0721T #0722T #AIReimbursement #BeckersHospitalReview #BeckersPayerIssues #Optellum I UnitedHealth Group I Humana I CVS Health (Aetna, a CVS Health Company)I Cigna Healthcare I Elevance Health I Kaiser Permanente I Kaiser Permanente Georgia I Johnathan Watkins I Prof Sir Michael Brady I Kevin Lim I Intuitive Ventures I Black Opal Ventures I Woori Venture Partners US (우리벤처파트너스) I Healthliant Ventures I Mercia Ventures I Becker's Healthcare

Every day, nearly 5,000 lives are lost to lung cancer. Early detection is critical, but so often, it comes too late. At Optellum, we're harnessing the power of advanced AI to help doctors catch lung cancer earlier, offering patients a fighting chance and families more precious moments together. Our Virtual Nodule Clinic empowers healthcare teams with cutting-edge tools to identify and treat lung cancer at its most treatable stages. Join us in the fight to end lung cancer. Learn more at www.optellum.com

Across the United States, hospitals use Optellum’s AI platform to identify and manage lung nodules more efficiently and with clear financial return. Optellum provides end-to-end enterprise AI for lung nodule management. It automatically discovers patients from radiology reports, applies an FDA-cleared cancer risk score from CT images, and supports structured follow-up and care coordination within existing clinical teams. Each use of Optellum’s Lung Cancer Prediction AI is eligible for CMS reimbursement at $650, enabling health systems to fund earlier diagnosis, improve follow-up rates, and increase appropriate downstream procedures without adding staff. Optellum is already deployed across US health systems as part of reimbursable lung nodule and early lung cancer pathways.